Literature DB >> 29311385

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Victor H Engelhard1,2, Anthony B Rodriguez3,2, Ileana S Mauldin3,4, Amber N Woods3,2, J David Peske3,2, Craig L Slingluff3,4.   

Abstract

Limited representation of intratumoral immune cells is a major barrier to tumor control. However, simply enhancing immune responses in tumor-draining lymph nodes or through adoptive transfer may not overcome the limited ability of tumor vasculature to support effector infiltration. An alternative is to promote a sustained immune response intratumorally. This idea has gained traction with the observation that many tumors are associated with tertiary lymphoid structures (TLS), which organizationally resemble lymph nodes. These peri- and intratumoral structures are usually, but not always, associated with positive prognoses in patients. Preclinical and clinical data support a role for TLS in modulating immunity in the tumor microenvironment. However, there appear to be varied functions of TLS, potentially based on their structure or location in relation to the tumor or the origin or location of the tumor itself. Understanding more about TLS development, composition, and function may offer new therapeutic opportunities to modulate antitumor immunity.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2018        PMID: 29311385      PMCID: PMC5777336          DOI: 10.4049/jimmunol.1701269

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  171 in total

Review 1.  The lymphocyte homing receptors: gatekeepers of the multistep paradigm.

Authors:  Robert Sackstein
Journal:  Curr Opin Hematol       Date:  2005-11       Impact factor: 3.284

2.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.

Authors:  Marie-Caroline Dieu-Nosjean; Martine Antoine; Claire Danel; Didier Heudes; Marie Wislez; Virginie Poulot; Nathalie Rabbe; Ludivine Laurans; Eric Tartour; Luc de Chaisemartin; Serge Lebecque; Wolf-Herman Fridman; Jacques Cadranel
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 44.544

Review 4.  Lymph node fibroblastic reticular cells in health and disease.

Authors:  Anne L Fletcher; Sophie E Acton; Konstantin Knoblich
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

5.  Expression of N-acetylglucosamine 6-O-sulfotransferases (GlcNAc6STs)-1 and -4 in human monocytes: GlcNAc6ST-1 is implicated in the generation of the 6-sulfo N-acetyllactosamine/Lewis x epitope on CD44 and is induced by TNF-alpha.

Authors:  Sie Lung Tjew; Kelly L Brown; Reiji Kannagi; Pauline Johnson
Journal:  Glycobiology       Date:  2005-02-23       Impact factor: 4.313

6.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

7.  Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma.

Authors:  Hiroaki Musha; Haruo Ohtani; Takayuki Mizoi; Makoto Kinouchi; Takashi Nakayama; Kennichi Shiiba; Kikuo Miyagawa; Hiroshi Nagura; Osamu Yoshie; Iwao Sasaki
Journal:  Int J Cancer       Date:  2005-10-10       Impact factor: 7.396

8.  Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs.

Authors:  Alexei V Tumanov; Sergei I Grivennikov; Andrei A Kruglov; Yuriy V Shebzukhov; Ekaterina P Koroleva; Yulan Piao; Chang-Yi Cui; Dmitry V Kuprash; Sergei A Nedospasov
Journal:  Blood       Date:  2010-07-15       Impact factor: 22.113

9.  Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function.

Authors:  Kalpit A Vora; Li Chun Wang; Sambasiva P Rao; Zhong-Ying Liu; Gerard R Majeau; Anne H Cutler; Paula S Hochman; Martin L Scott; Susan L Kalled
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

Review 10.  Ectopic lymphoid tissues and local immunity.

Authors:  Damian M Carragher; Javier Rangel-Moreno; Troy D Randall
Journal:  Semin Immunol       Date:  2008-02-19       Impact factor: 11.130

View more
  70 in total

1.  Characterization and comparison of innate and adaptive immune responses at vaccine sites in melanoma vaccine clinical trials.

Authors:  Marit M Melssen; Karlyn E Pollack; Max O Meneveau; Mark E Smolkin; Joel Pinczewski; Alexander F Koeppel; Stephen D Turner; Katia Sol-Church; Alexandra Hickman; Donna H Deacon; Gina R Petroni; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2021-01-16       Impact factor: 6.968

2.  Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Authors:  Katie M Leick; Joel Pinczewski; Ileana S Mauldin; Samuel J Young; Donna H Deacon; Amber N Woods; Marcus W Bosenberg; Victor H Engelhard; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2019-05-27       Impact factor: 6.968

Review 3.  B cells, plasma cells and antibody repertoires in the tumour microenvironment.

Authors:  George V Sharonov; Ekaterina O Serebrovskaya; Diana V Yuzhakova; Olga V Britanova; Dmitriy M Chudakov
Journal:  Nat Rev Immunol       Date:  2020-01-27       Impact factor: 53.106

4.  Multiplex Immunofluorescence Histology for Immune Cell Infiltrates in Melanoma-Associated Tertiary Lymphoid Structures.

Authors:  Ileana S Mauldin; Adela Mahmutovic; Samuel J Young; Craig L Slingluff
Journal:  Methods Mol Biol       Date:  2021

5.  Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.

Authors:  Anne M Stowman; Alexandra W Hickman; Ileana S Mauldin; Adela Mahmutovic; Alejandro A Gru; Craig L Slingluff
Journal:  Melanoma Res       Date:  2018-06       Impact factor: 3.599

Review 6.  Insights into Tumor-Associated Tertiary Lymphoid Structures: Novel Targets for Antitumor Immunity and Cancer Immunotherapy.

Authors:  Anthony B Rodriguez; Victor H Engelhard
Journal:  Cancer Immunol Res       Date:  2020-11       Impact factor: 11.151

7.  Deconvolution of the immunological contexture of mouse tumors with multiplexed immunohistochemistry.

Authors:  Ileana S Mauldin; Natasha D Sheybani; Samuel J Young; Richard J Price; Craig L Slingluff
Journal:  Methods Enzymol       Date:  2019-06-29       Impact factor: 1.600

Review 8.  PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.

Authors:  Christopher D Nishimura; Marc C Pulanco; Wei Cui; Liming Lu; Xingxing Zang
Journal:  Trends Mol Med       Date:  2020-11-13       Impact factor: 11.951

Review 9.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

10.  Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice.

Authors:  Simone Ragusa; Borja Prat-Luri; Alejandra González-Loyola; Sina Nassiri; Mario Leonardo Squadrito; Alan Guichard; Sabrina Cavin; Nikolce Gjorevski; David Barras; Giancarlo Marra; Matthias P Lutolf; Jean Perentes; Emily Corse; Roberta Bianchi; Laureline Wetterwald; Jaeryung Kim; Guillermo Oliver; Mauro Delorenzi; Michele De Palma; Tatiana V Petrova
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.